KLK3 and neoplasm: Provocative data from our team have suggested that it may be possible to modulate the impact of mitoxantrone by the use of tesmilifene, a xenobiotic that alters the function of cytochrome P450 and which alters the function of multidrug resistance protein, thus altering the exposure of tumor cells to the active agent.[14] In a phase II trial, we demonstrated a surprising proportion of patients with very advanced, AIPC to be alive at 2 and 3 years, consequent upon an initial PSA response rate of more than 60%.[14]